<DOC>
	<DOCNO>NCT01380301</DOCNO>
	<brief_summary>Cutaneous leishmaniasis endemic New World , recently , standard treatment pentavalent antimony . The cure rate L panamensis Colombia 91 % -93 % cure rate Bolivia also 90 % . Nevertheless , pentavalent antimonials disadvantage multiple injection mild-moderate clinical toxicity particularly unpleasant moderate clinical problem cutaneous leishmaniasis . The oral agent Miltefosine show effective antimony Colombia Bolivia ( 91 92 % respectively ) . Side effect see patient cutaneous disease specifically attribute drug nausea vomit mild grade approximately 25 % patient , low-grade elevation creatinine also approximately 25 % patient . A disadvantage miltefosine regimens short 4 week evaluate cutaneous disease . Combination therapy use many infectious disease , tuberculosis , malaria , HIV . Combination therapy offer potential prevent drug resistance , organism resistant one drug may susceptible drug ; also potential diminish drug therapy duration thus side effect . These two potential benefit extent contradict : preventing resistance best do full course drug use ; diminish therapy duration mean use le full course drug . The optimum combination regimen one sufficient amount drug use high efficacy , yet amount low possible spare patient unnecessarily long courses drug . In present protocol , combination half-course miltefosine half-course antimony evaluate efficacy tolerance . The combination miltefosine antimony choose two standard agent Bolivia , vitro combination additive mildly synergistic standard leishmania strain .</brief_summary>
	<brief_title>Treatment Cutaneous Leishmaniasis With Combination Miltefosine Antimony</brief_title>
	<detailed_description />
	<mesh_term>Leishmaniasis</mesh_term>
	<mesh_term>Leishmaniasis , Cutaneous</mesh_term>
	<mesh_term>Miltefosine</mesh_term>
	<criteria>Parasitological confirmation least 1 lesion must ulcerative No specific antileishmanial therapy previous six month Concomitant disease Tuberculosis , HIV , diabetes , renal failure , liver disease abnormality CTC 2 blood , liver , kidney test EKG</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>Leishmaniasis</keyword>
	<keyword>Miltefosine</keyword>
	<keyword>Antimony</keyword>
	<keyword>Therapy</keyword>
</DOC>